Prevalence and treatment of cardiovascular disease and traditional risk factors in Australian adults with renal insufficiency

Nephrology

Volumn 10, Issue 1, 2005, Pages 40-47

  Briganti, Esther M ^a,d   Kerr, Peter G ^b   Shaw, Jonathan E ^c   Zimmet, Paul Z ^c   Atkins, Robert C ^b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d ALFRED HOSPITAL   (Australia)

Author keywords

Cardiovascular disease; Cardiovascular risk factors; Epidemiology; Population study; Renal insufficiency

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; AUSTRALIA; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADULT; AGED; ANGINA PECTORIS; AUSTRALIA; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREVALENCE; RISK FACTORS; SMOKING;

EID: 14844320090     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00357.x     Document Type: Review

References (35)

1. Chadban SJ, Briganti EM, McNeil JJ, Zimmet PZ, Atkins RC. Prevalence of kidney damage in Australian adults - the AusDiab Kidney Study. J. Am. Soc. Nephrol. 2003; 14 (Suppl.): S131-8.
2. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal failure. J. Am. Soc. Nephrol. 1998; 9 (Suppl.): S16-23.
3. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-19.
4. Shlipak MG, Fried LF, Crump C et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int. 2002; 62: 997-1004.
5. Dunstan DW, Zimmet PZ, Welborn TA et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) - methods and response rates. Diabetes Res. Clin. Pract. 2002; 57: 119-29.
6. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am. Heart J. 1991; 121: 293-8.
7. National Heart Foundation. 1999 Guide to Management of Hypertension for Doctors. Canberra: National Heart Foundation, 1999.
8. Anonymous. The lipid management guidelines-2001. MJA 2001; 175 (Suppl.): S62-S8.
9. Anonymous. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999.
10. StataCorp. Stata Statistical Software, Release 8.0. College Station, Tex: StataCorp, 2003.
11. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: A possible marker for increased risk of stroke. Stroke 1997; 28: 557-63.
12. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke 1996; 27: 1479-86.
13. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002; 62: 1402-7.
14. Fried LF, Shlipak MG, Crump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J. Am. Coll. Cardiol. 2003; 41: 1364-72.
15. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES 1. Kidney Int. 2002; 61: 1486-94.
16. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J. Am. Soc. Nephrol. 2002; 13: 745-53.
17. Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol. Dial. Transplant. 1998; 13: 3091-5.
18. Anonymous. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.
19. Asai Y, Heller R, Kajii E. Hypertension control and medication increase in primary care. J. Hum. Hypertens. 2002; 16: 313-18.
20. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: The WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44 (Suppl.): S54-64.
21. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch. Intern. Med. 2000; 160: 1093-100.
22. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240: 37-42.
23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329: 977-86.
24. Anonymous. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol 1995; 75: 894-903.
25. Abraira C, Colwell JA, Nuttall FQ et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study Type II Diabetes. Diabetes Care 1995; 18: 1113-23.
26. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
27. Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
28. Jungers P, Massy ZA, Nguyen Khoa T et al. Incidence and risk factors of atherosclerostic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol. Dial. Transplant. 1997; 12: 2597-602.
29. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J. Am. Soc. Nephrol. 2001; 12: 1516-23.
30. Foley RN, Herzog CA, Collins A. Smoking and cardiovascular outcomes in dialysis patients. The United States Renal Data System Wave 2 Study. Kidney Int. 2003; 63: 1462-7.
31. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch. Intern. Med. 1995; 155: 1073-80.
32. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int. 2001; 59: 260-9.
33. Anonymous. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control. Complications (DCCT) Research Group. Kidney Int. 1995; 47: 1703-20.
34. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. N. Engl. J. Med. 2000; 342: 381-9.
35. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.